source
- Aspen Neuroscience and Bambusa Therapeutics each target $134 million IPOsAspen Neuroscience, a cell‑therapy company focused on Parkinson's disease, and Bambusa Therapeutics, a bispecific biotech, have filed SEC documents outlining plans for initial public offerings. Bo…
- Leak of Moderna-Merck cancer vaccine phase 3 data sparks drama at ESMO 2026 conferenceThe European Society for Medical Oncology (ESMO) meeting this year was marked by an unexpected leak of phase 3 results for a cancer vaccine being developed by Moderna and Merck. The data appeared t…